PharmaTelevision - Minomic: Innovative Testing and New Products

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Minomic: Innovative Testing and New Products

Visitors: You are watching a 30 seconds preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks with Brad Walsh, CEO at Minomic International.

Filmed at AusBiotech 2009, they discuss:

• Minomic as a non-invasive diagnostic company
• proteins that are linked to prostate cancer
• unique tests and Minomic's secretive new marker
• diabetes as a growing disease
• when Minomic plans to have their new products on the market

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Minomic International as a non-invasive diagnostic company.

Fintan Walton:

Hello and welcome to PharmaTelevision news review here in Melbourne, Australia. On this show I have Brad Walsh , who is CEO of a company called Minomic International's, which is based in Sydney, Australia. Welcome to the show.

Brad Walsh:

Thank you very much.

Fintan Walton:

Brad Walsh , your company is a diagnostics company, there are lots of diagnostics companies are out there not just in Australia but around the world but what is your diagnostics company all about?

Brad Walsh:

Our diagnostics company is about having non-invasive diagnostics, so we're using urine as an sample for our tests and we're working on two diagnostics-Kits and the lead one is for Prostate Cancer and the second one is for Type 2 Diabetes.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Brad Walsh

CEO

Dr Brad Walsh Chief Executive Officer, has 25 years experience in the biotechnology business and has enjoyed a successful career commercializing immunoassay kits and proteomics technologies and consumables as well as bioinformatics software. His products are being sold and supplied by major us corporations like Waters and Bio-Rad. Before founding Minomic International he was general manager of a not-for-profit public entity called the Australian Proteome Analysis Facility. This was a multi-million dollar facility established in 1995 by the Federal Government. Prior to this he led research groups in public institutions such as CSIRO, universities and hospitals. With his background and having successfully guided Minomic International and MPL through six of the most turbulent years in biotech, both industry and government have eagerly sought his opinion as a thought leader and technologist. He has won prizes for the products being developed by the Company and was responsible for putting MPL on the 2006 business review weekly upstarts list of 200 fastest growing start-up companies.

Minomic International

Minomic Internationalwas established in 2007, as a company that commercializes late stage biotechnology development projects. The first two diagnostic products for the detection of Prostate Cancer and the detection of Type 2 Diabetes will be Minomic International's flagship commercialization projects. Both diagnostic products are urine based tests and will offer significant advantages over the dominant, more invasive screening methods currently used for detecting each disease. With the ability to identify and test reliably for biomarkers of diseases such as cancer and diabetes, Minomic International is in a niche and growing market with few rivals. The technology has major opportunities for rapid product range extension in diseases where traditional tests are limited or inadequate. Proteomics is revolutionizing protein moleculardiagnostics through the discovery of protein biomarkers and panels of biomarkers that may be developed into highly predictive diagnostic tests. These tests will provide improved patient care as well as providing pharmacoproteomic services that lead to improved drug toxicology, efficacy and theranostic assays. Minomic International has an impressive board of directors and management team, ensuring that the company is well equipped for global expansion and future development projects.